Correspondence 0001104659-23-046243 from Enfusion, Inc. (ENFN) (CIK 0001868912)
Enfusion, Inc. (ENFN) (CIK 0001868912)
Date: April 17, 2023 · CIK: 0001868912 · Accession: 0001104659-23-046243
AI Filing Summary & Sentiment
File numbers found in text: 001-40949
Letter
VIA EDGAR Division of Corporation Finance Office of Technology United States Securities and Exchange Commission Form 10-K for the Fiscal Year Ended December 31, 2022 Filed March 10, 2023 Form 8-K Furnished on March 7, 2023 File No. 001-40949
Dear Mr. Edgar:
Enfusion, Inc. (“we,” “us” and “our”) hereby acknowledges receipt of the letter (the “Comment Letter”), dated April 14, 2023, containing comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange Commission.
The Comment Letter requests that we respond to the Staff’s comments within ten business days or advise the Staff when we will provide the Staff with our responses. As previously discussed, we respectfully request an extension of time to respond to the Comment Letter so that we can devote appropriate time and resources to consider the Staff’s comments and to complete our responses. We expect to provide our responses to the Comment Letter no later than May 12, 2023.
If you have any questions, please do not hesitate to call the undersigned at (312) 724-8981.
Sincerely,
/s/ Matthew
R. Campobasso
Show Raw Text
CORRESP
1
filename1.htm
April 17, 2023
VIA EDGAR
David Edgar
Division of Corporation Finance
Office of Technology
United States Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re: Enfusion, Inc.
Form 10-K for the Fiscal Year
Ended December 31, 2022
Filed March 10, 2023
Form 8-K Furnished on March 7, 2023
File No. 001-40949
Dear Mr. Edgar:
Enfusion, Inc. (“we,”
“us” and “our”) hereby acknowledges receipt of the letter (the “Comment Letter”), dated April 14,
2023, containing comments of the staff of the Division of Corporation Finance (the “Staff”) of the Securities and Exchange
Commission.
The Comment Letter requests
that we respond to the Staff’s comments within ten business days or advise the Staff when we will provide the Staff with our responses.
As previously discussed, we respectfully request an extension of time to respond to the Comment Letter so that we can devote appropriate
time and resources to consider the Staff’s comments and to complete our responses. We expect to provide our responses to the Comment
Letter no later than May 12, 2023.
If you have any questions,
please do not hesitate to call the undersigned at (312) 724-8981.
Sincerely,
/s/ Matthew
R. Campobasso
Matthew R. Campobasso
General Counsel and Secretary
cc: Brad
Herring, Chief Financial Officer, Enfusion, Inc.